BMO Capital analyst Jeffrey Silber maintains Gartner (NYSE:IT) with a Market Perform and raises the price target from $356 to $357.
Travere Therapeutics Announces Late-Breaking Data From Phase 3 Studies Of Sparsentan In IgAN And FSGS Published In The Lancet And The NEJM Respectively And Presented At The American Society Of Nephrology Kidney Week 2023
Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparsentan has the potential to preserve kidney function and significantly delay time to kidney failure, suggesting
